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Tandem duplications contribute to not one but two distinct phenotypes Johnathan Watkins 1, 2, 3 , Andrew N Tutt 2, 3, 4 , Anita Grigoriadis 1,2,3* Menghi and co-workers report a metric to classify tumours into those with and without a tandem duplicator phenotype (TDP) using the frequency of tandem duplications (TDs) in 277 whole genome sequenced samples (1) . Building on a previous method (2), the authors identified TDs from SNP array data, and found that the TDP was strongly associated with response to the DNA damaging chemotherapeutic, cisplatin. These findings supplement the growing recognition that genome-wide signatures of mutator phenotypes may prove to be important additions to the companion diagnostic repertoire (3, 4) .
Although the findings of this report are highly stimulating, accumulating evidence suggests that an elevated abundance of TDs features in not just one but two distinct phenotypes.
Two of the original studies on the TDP reported a mutual exclusion with BRCA1/2 inactivation (2, 5), which conflicts with the enrichment of BRCA1 loss among TDP cancers observed by Menghi and colleagues. Using TCGA breast cancer data (6), we established allele-specific copy number profiles using ASCAT (7) before calling TDP status as described previously (2) (Fig. 1A) ; however, we found no instances of tumours with BRCA1 inactivation among 2-10Mbp TDP cancers (Fig. 1B) .
Furthermore, while 56% of the Menghi et al study's TDP calls were shared with our 1Kbp-2Mbp TDP calls, only 10% of the Menghi et al study's TDP calls agreed with our 2-10Mbp TDP calls (Fig. 1C) . In addition, we found that In conclusion, we propose that there are actually two TDPs, with the study by 
